

12 January 2026

ASX Announcement

Update on Registration of Nasodine in the Philippines

Firebrick Pharma Limited (ASX:FRE) (Company or Firebrick) is pleased to advise that the registration process for Nasodine Nasal Spray (“Nasodine”) in the Philippines has progressed.

The registration dossier was filed with the Philippines Food and Drug Administration (“PFDA”) in November 2025, by the Company’s Philippines licensing partner SV More Pharma Corporation (“SV More Pharma”).

On 9 January 2026, the Company was advised by SV More Pharma that the dossier had now passed pre-assessment by PFDA and that the formal review will now commence. The PFDA review is expected to take at least 6 months.

“This points to potential approval in 2026, which will be an important milestone for Firebrick,” said Firebrick Executive Chairman, Dr Peter Molloy. “The Philippines is a large pharmaceutical market, where we have a strong marketing partner and strategic investor.” SV More is a substantial investor in Firebrick through its affiliate, Pharma Nutria N.A., Inc. (announcement 16 October 2025).

The filing of the registration dossier in November 2025 follows the successful manufacturing of several GMP batches of Nasodine in the Philippines in early 2025, and subsequent successful completion of 6 months’ stability testing and dossier preparation. As previously reported (announcement 15 August 2024), advice obtained by SV More Pharma from the PFDA indicated that provided Nasodine is manufactured in the Philippines, the product would be classified as a ‘disinfectant spray for the nasal passages’ and would only require a manufacturing dossier, without clinical efficacy studies, for approval. This dossier has now been submitted and accepted for review.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Ltd.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has successfully developed and manufactured Nasodine® Nasal Spray (0.5% PVP-I), which so far has been introduced into the United States, Singapore and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines. Firebrick also recently announced the successful development and upcoming launch in existing markets of its first follow-on product in the portfolio, Nasodine® Throat Spray, to be marketed as a convenient substitute for PVP-I throat gargles.

Media enquiries:

Heidi Cuthbert
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com